2seventy bio to lay off 40% of workforce; CEO to step down
Reuters
Published Sep 12, 2023 07:39AM ET
Updated Sep 12, 2023 09:31AM ET
(Reuters) -2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma, lifting the company's shares more than 8% in premarket trade.
The company added that CEO Nick Leschly will step down and transition to the role of chairman. Leschly was earlier the CEO of bluebird bio for 11 years, but changed role after the gene therapy maker's oncology portfolio was spun off from it as 2seventy.
2seventy said on Tuesday that by eliminating 176 roles it will save about $130 million in 2024-25 that will be used to increase its focus on Abecma.
Abecma competes with Carvykti, a cell therapy from Johnson & Johnson (NYSE:JNJ) and Legend Biotech, as a fifth line treatment for patients with multiple myeloma - a type of blood cancer.
The two therapies work by collecting a type of white blood cells from a patient, genetically modifying them to fight a cancer and then infusing back into a patient.
2seventy bio and partner Bristol Myers (NYSE:BMY) Squibb equally split profits from Abecma, which recorded $115 mln in U.S. sales in the second quarter.
However, the original group of eligible multiple myeloma patients who needed the therapy have largely been addressed, and now the demand will only be driven by additional patients, 2seventy Chief Financial Officer William Baird had said during an investor conference call last month.
The company will now focus on another type of multiple myeloma patients, for which it expects approval from the U.S. Food and Drug Administration in mid-December.
2seventy said on Tuesday it expects a decline in sales of Abecma in the third quarter and U.S. revenue for the therapy in 2023 could be lower than the $470-$570 million range it previously projected.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.